title: Plasmodium falciparum pfmdr1 amplification, mefloquine resistance, and parasite fitness.
abstract: Mefloquine is widely used in combination with artemisinin derivatives for the treatment of falciparum malaria. Mefloquine resistance in Plasmodium falciparum has been related to increased copy numbers of multidrug-resistant gene 1 (pfmdr1). We studied the ex vivo dynamics of pfmdr1 gene amplification in culture-adapted P. falciparum in relation to mefloquine resistance and parasite fitness. A Thai P. falciparum isolate (isolate TM036) was assessed by the use of multiple genetic markers as a single genotype. Resistance was selected by exposure to stepwise increasing concentrations of mefloquine up to 30 ng/ml in continuous culture. The pfmdr1 gene copy numbers increased as susceptibility to mefloquine declined (P = 0.03). No codon mutations at positions 86, 184, 1034, 1042, and 1246 in the pfmdr1 gene were detected. Two subclones of selected parasites (average copy numbers, 2.3 and 3.1, respectively) showed a fitness disadvantage when they were grown together with the original parasites containing a single pfmdr1 gene copy in the absence of mefloquine; the multiplication rates were 6.3% and 8.7% lower, respectively (P < 0.01). Modeling of the dynamics of the pfmdr1 copy numbers over time in relation to the relative fitness of the parasites suggested that net pfmdr1 gene amplification from one to two copies occurs once in every 10(8) parasites and that amplification from two to three copies occurs once in every 10(3) parasites. pfmdr1 gene amplification in P. falciparum is a frequent event and confers mefloquine resistance. Parasites with multiple copies of the pfmdr1 gene have decreased survival fitness in the absence of drug pressure.
authors.affiliation: Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
authors.forename: Piyanuch
authors.initials: P
authors.lastname: Preechapornkul
authors.forename: Mallika
authors.initials: M
authors.lastname: Imwong
authors.forename: Kesinee
authors.initials: K
authors.lastname: Chotivanich
authors.forename: Wirichada
authors.initials: W
authors.lastname: Pongtavornpinyo
authors.forename: Arjen M
authors.initials: AM
authors.lastname: Dondorp
authors.forename: Nicholas P J
authors.initials: NP
authors.lastname: Day
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: White
authors.forename: Sasithon
authors.initials: S
authors.lastname: Pukrittayakamee
mesh_terms: D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D005784:Gene Amplification; D018628:Gene Dosage; D005838:Genotype; D016778:Malaria, Falciparum / Q000188:drug therapy* / Q000235:genetics; D015767:Mefloquine / Q000494:pharmacology*; D027425:ATP-Binding Cassette, Sub-Family C Proteins / Q000235:genetics*
chemical_list: D000962:Antimalarials; D015767:Mefloquine; D027425:ATP-Binding Cassette, Sub-Family C Proteins; C513498:Mdr1 protein, Plasmodium falciparum